China-based Betta Pharma has announced plans for a Hong Kong Stock Exchange (HKEX) secondary listing seeking to raise capital through issuance of up to 15% of its total shares to fund international expansion and clinical development. The company previously attempted HKEX listings in 2021 without success but now aims to leverage this offering to advance its international commercialisation efforts particularly for ALK inhibitor ensartinib, which last year received US market approval for ALK-positive NSCLC. The listing proceeds will support research activities, potential acquisitions and market expansion initiatives.

Betta Pharma's revenue reached RMB 1.73 billion in H1 2025, with core products icotinib and ensartinib contributing over 10% each. The company is transitioning from domestic focus to global competition with ensartinib's European Medicines Agency (EMA) submission underway and ophthalmology asset EYP-1901 in Phase III trials for wet age-related macular degeneration (wAMD). Betta Pharma's strategy combines licensing agreements with equity investments in international biotech companies, having acquired global rights to multiple assets including PROTAC candidate CFT8919 for EGFR L858R mutations.

According to PharmCube's NextBiopharm® database, Betta has entered a total 12 in-licensing deals so far. Click here to request a free trial for NextBiopharm®.